Home > Boards > Free Zone > Industry Specific > Mining Sector Ideas
Followed By 70
Posts 27621
Boards Moderated 80
Alias Born 03/22/2005

Tuesday, April 12, 2022 9:25:11 PM

Re: None

Post# of 272
>>> Uranium Miner Cameco Catches an Upgrade. Russia Is the Reason.


By Al Root

April 11, 2022


Cameco operates a uranium-processing plant in Port Hope, Ontario, Canada.

Uranium miner Cameco caught an upgrade Monday from the Street, which pushed the stock higher initially. Things are pretty good for the company right now—and they’re set to get better.

RBC analyst Andrew Wong changed his rating on Cameco (ticker: CCJ) stock to Buy from Hold. His price target went to $50CDN a share from $30. The U.S. dollar price targets are roughly $40 and $24, respectively. Cameco has both U.S. and Canadian stock listings.

Shares were up about 1.4% in early trading, then dipped into the red. The S&P 500 and Dow Jones Industrial Average were down 1.2% and 0.5%, respectively.

The stock has been strong. Shares are up roughly 50% since Russia invaded Ukraine in late February, for primarily two reasons.

First, the war raised the possibility that Europe would turn from using less natural gas-generated power—the continent’s countries buy large supplies of natural gas from Russia—and more nuclear power. And second, Russia is also a supplier of uranium to nuclear-power plants. If that supply gets hit by sanctions from the West, commodity markets would tighten even more, and Cameco more than like would pick up more business as one of the world’s largest uranium producers.

The Russia-Ukraine war was a key factor in Wong’s upgrade.

“We believe the Russia/Ukraine war and subsequent shift in Western markets away from exposure to Russia have fundamentally changed the uranium market outlook and long-term market structure,” wrote the analyst Monday. “We see Cameco as best-positioned to meet market needs in this transition with Western-based proven and potential production along the nuclear fuel cycle.”

All analysts covering Cameco rate shares Buy; before the invasion, about 85% of analysts recommended the stock. The average Buy-rating ratio for stocks in the S&P is 58%.

The average analyst price target is about $32 a share, up from $29 just before the invasion.


OTC: ILUS, ILUS International (Ilustrato Pictures International Inc.) Confirms the Settlement of Two $500,000 Notes and Announces a Further $5.6 Million in Funding ILUS Aug 8, 2022 1:49 PM

Progressive Care Announces Launch of New Logo as It Continues to Upgrade and Strengthen Its PharmcoRx Brand RXMD Aug 8, 2022 10:42 AM

Current Developments at Argentum 47, Inc. and Roadmap to 2023 ARGQD Aug 8, 2022 10:29 AM

Kona Gold Beverage, Inc Expands Sales Team KGKG Aug 8, 2022 9:00 AM

The Power of Science to Stop a Killer NVS Aug 8, 2022 8:45 AM

Mru Patel Appointed Non-Executive Director of Axis Technologies Group, Inc. AXTG Aug 5, 2022 9:00 AM

HealthLynked to Premier "Forever: The End of Aging" Medical Documentary atCMX CinéBistro Theater in Naples, Florida on August 28th HLYK Aug 5, 2022 8:00 AM

Progressive Care Announces Shareholder Conference Call and Business Update on August 11, 2022 RXMD Aug 5, 2022 7:15 AM

IGEN announces Net Profit for Second Quarter 2022 IGEN Aug 5, 2022 7:08 AM

Kaya Holdings to Seek Licenses for First Ever State Legal Psilocybin Manufacturing and Facilitation Service Centers in Oregon KAYS Aug 4, 2022 12:44 PM

American Rebel Holdings Completes Acquisition of Champion Safe Company, Solidifying A Leading Position in Safe Industry AREBW Aug 4, 2022 10:27 AM

OTC: ILUS, ILUS International (Ilustrato Pictures International Inc), Summarizes Its Second Quarter of 2022 Results, Including a 588% Revenue Increase Over the Same Period in 2021 ILUS Aug 4, 2022 10:19 AM

New Intranet- and Cloud-based Monitoring and Management Interface Enhances ResGreen's BotWay Software RGGI Aug 3, 2022 10:53 AM

Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics TOMDF Aug 3, 2022 9:48 AM